Autoantibody repertoire profiling in tissue and blood identifies colorectal cancer‐specific biomarkers

Abstract

AbstractAutoantibodies (AAbs) in the blood of colorectal cancer (CRC) patients have been evaluated for tumor detection. However, it remains uncertain whether these AAbs are specific to tumor‐associated antigens. In this study, we explored the IgG and IgM autoantibody repertoires in both the in situ tissue microenvironment and peripheral blood as potential tumor‐specific biomarkers. We applied high‐density protein arrays to profile AAbs in the tumor‐infiltrating lymphocyte supernatants and corresponding serum from four patients with CRC, as well as in the serum of three noncancer controls. Our findings revealed that there were more reactive IgM AAbs than IgG in both the cell supernatant and corresponding serum, with a difference of approximately 3–5 times. Immunoglobulin G was predominant in the serum, while IgM was more abundant in the cell supernatant. We identified a range of AAbs present in both the supernatant and the corresponding serum, numbering between 432 and 780, with an average of 53.3% shared. Only 4.7% (n = 23) and 0.2% (n = 2) of reactive antigens for IgG and IgM AAbs, respectively, were specific to CRC. Ultimately, we compiled a list of 19 IgG AAb targets as potential tumor‐specific AAb candidates. Autoantibodies against one of the top candidates, p15INK4b‐related sequence/regulation of nuclear pre‐mRNA domain‐containing protein 1A (RPRD1A), were significantly elevated in 53 CRC patients compared to 119 controls (p < 0.0001). The project revealed that tissue‐derived IgG AAbs, rather than IgM, are the primary source of tumor‐specific AAbs in peripheral blood. It also identified potential tumor‐specific AAbs that could be applied for noninvasive screening of CRC.